Novavax Stock Price

-0.92 (-0.84%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Novavax Inc NVAX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
5.65 5.42% 109.97 99.15 112.77 107.20 104.32 20:00:00
Bid Price Ask Price Spread Spread % News
108.75 109.30 0.55 0.5% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
56,940 5,390,823 $ 105.47 $ 568,576,517 7,783,704 3.54 - 113.98
Last Trade Time Type Quantity Stock Price Currency
19:59:31 1 $ 109.05 USD

Novavax Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 6.45B 58.69M 58.48M $ 18.66M $ - -5.62 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 1.50k 4.30%

more financials information »

Novavax News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NVAX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week104.03113.9893.00102.2610,008,3575.945.71%
1 Month51.18113.9848.2181.988,537,23258.79114.87%
3 Months24.04113.9816.4152.359,461,16485.93357.45%
6 Months3.91113.983.7730.949,103,223106.062,712.53%
1 Year4.90113.983.5428.444,960,440105.072,144.29%
3 Years23.40113.983.5428.746,770,61286.57369.96%
5 Years239.40300.203.5450.607,001,804-129.43-54.06%

Novavax Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.